These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 25484045)

  • 21. The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells.
    Liu F; Si Y; Liu G; Li S; Zhang J; Ma Y
    Biomed Pharmacother; 2015 Mar; 70():41-5. PubMed ID: 25776477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
    Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
    Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.
    Beyrath J; Chekkat N; Smulski CR; Lombardo CM; Lechner MC; Seguin C; Decossas M; Spanedda MV; Frisch B; Guichard G; Fournel S
    Oncotarget; 2016 Oct; 7(40):64942-64956. PubMed ID: 27409341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity.
    Uberti D; Ferrari-Toninelli G; Bonini SA; Sarnico I; Benarese M; Pizzi M; Benussi L; Ghidoni R; Binetti G; Spano P; Facchetti F; Memo M
    Neuropsychopharmacology; 2007 Apr; 32(4):872-80. PubMed ID: 16936710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
    Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
    Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis.
    Swers JS; Grinberg L; Wang L; Feng H; Lekstrom K; Carrasco R; Xiao Z; Inigo I; Leow CC; Wu H; Tice DA; Baca M
    Mol Cancer Ther; 2013 Jul; 12(7):1235-44. PubMed ID: 23645592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
    Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
    Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel agonistic anti-human death receptor 5 monoclonal antibody with tumoricidal activity induces caspase- and mitochondrial-dependent apoptosis in human leukemia Jurkat cells.
    Du YW; Chen JG; Bai HL; Huang HY; Wang J; Li SL; Liu GC; Jiang Q; Chai J; Zhao YP; Ma YF
    Cancer Biother Radiopharm; 2011 Apr; 26(2):143-52. PubMed ID: 21539448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.
    Meng RD; McDonald ER; Sheikh MS; Fornace AJ; El-Deiry WS
    Mol Ther; 2000 Feb; 1(2):130-44. PubMed ID: 10933923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
    Haynes NM; Hawkins ED; Li M; McLaughlin NM; Hämmerling GJ; Schwendener R; Winoto A; Wensky A; Yagita H; Takeda K; Kershaw MH; Darcy PK; Smyth MJ
    J Immunol; 2010 Jul; 185(1):532-41. PubMed ID: 20505139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity.
    Finnberg NK; Gokare P; Navaraj A; Lang Kuhs KA; Cerniglia G; Yagita H; Takeda K; Motoyama N; El-Deiry WS
    Cancer Res; 2016 Feb; 76(3):700-12. PubMed ID: 26609054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
    Lin YD; Chen S; Yue P; Zou W; Benbrook DM; Liu S; Le TC; Berlin KD; Khuri FR; Sun SY
    Cancer Res; 2008 Jul; 68(13):5335-44. PubMed ID: 18593935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.
    Qiao C; Hu M; Guo L; Lv M; Lin Z; Geng J; Lang X; Li X; Li Y; Ma Y; Feng J; Shen B
    BMC Immunol; 2012 Jul; 13():40. PubMed ID: 22788777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caspase-dependent molecular mechanisms of anti-human DR5 monoclonal antibody mDRA-6 inducing apoptosis of human leukemia Jurkat cells.
    Du YW; Liu GC; Wang J; Zhao YP; Li SL; Chen JG; Jiang Q; Cai J; Ma YF
    Ai Zheng; 2009 Feb; 28(2):112-6. PubMed ID: 19550122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
    Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
    Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types.
    Kaplan-Lefko PJ; Graves JD; Zoog SJ; Pan Y; Wall J; Branstetter DG; Moriguchi J; Coxon A; Huard JN; Xu R; Peach ML; Juan G; Kaufman S; Chen Q; Bianchi A; Kordich JJ; Ma M; Foltz IN; Gliniak BC
    Cancer Biol Ther; 2010 Apr; 9(8):618-31. PubMed ID: 20150762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.
    Zhang S; Zheng C; Zhu W; Xiong P; Zhou D; Huang C; Zheng D
    Theranostics; 2019; 9(18):5412-5423. PubMed ID: 31410224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.